Fiche du document
2010
- handle: 10670/1.e3tmzf
- hal: hal-00468340
- doi: 10.1080/09537280903441971
- PRODINRA: 36692
- WOS: 000275196700008
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1080/09537280903441971
Mots-clés
hub firm network business model biotechnology value chainSujets proches
Businesses Firms Companies Enterprises Business organizations Organizations, BusinessCiter ce document
Valérie Sabatier et al., « Orchestrating networks in the biopharmaceutical industry: small hub firms can do it », HAL-SHS : droit et gestion, ID : 10.1080/09537280903441971
Métriques
Partage / Export
Résumé
The biopharmaceutical industry has been one of the most dynamic and promising sectors. The entry of Biotechnology start-ups in the 1980s led to the reconfiguration of the drug development value chain and the emergence of new competences. As the sector evolved, specialised firms appeared. As the industry matures, the production process becomes more specialised to support optimisation of technological steps. Our case studies reveal that the coordination of networks can be specialised, with the emergence of Dedicated Coordinating Firms. On the basis of four case studies of European biotechnology companies within a business model approach, this article helps understanding how coordinating a network can be successful and how small hub firms can do it.